---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-25-001006"
form_type: "8-K"
ticker: "PLSE"
cik: "0001625101"
company_name: "PULSE BIOSCIENCES, INC."
filed_at: "2025-01-13T23:59:59+00:00"
generated_at: "2026-05-28T03:25:35.455102+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Pulse Biosciences appoints Paul LaViolette as CEO; grants 1.5M stock options with revenue/market cap milestones

## Summary
- Paul LaViolette, former Co-Chairman, becomes CEO and President effective Jan 9, 2025.
- Employment: $725k base salary, 70% target bonus, and option to purchase 1.5M shares at $18.43.
- Options vest 30% time-based over 4 years; 70% performance-based tied to market cap ($3B–$9B) and GAAP revenue/margin targets.
- Company also granted inducement options for 138,800 shares to 11 new employees at $18.55.
- Pulse to present at JP Morgan Healthcare Conference Jan 15; nano-PFA cardiac systems in clinical studies.

## SEC filing metadata
- accession: 0001437749-25-001006
- form_type: 8-K
- ticker: PLSE
- cik: 0001625101
- company_name: PULSE BIOSCIENCES, INC.
- filed_at: 2025-01-13T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1625101/000143774925001006/0001437749-25-001006-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1625101/000143774925001006/plse20250109_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-25-001006
- JSON: https://secwatch.observer/filing/0001437749-25-001006.json
- Plain text: https://secwatch.observer/filing/0001437749-25-001006.txt

## Key facts
- Executive change
  Paul A. LaViolette was appointed as Chief Executive Officer and President at PULSE BIOSCIENCES, INC..
  - Action: appointed
  - Role: Chief Executive Officer and President
  source text: The Board of Directors of Pulse Biosciences, Inc. (the “Company”) has appointed Paul A. LaViolette, current Co-Chairman of the Board, as Chief Executive Officer and President of the Company, effective as of January 9, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1625101/000143774925001006/0001437749-25-001006-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.